Contrasting Peregrine Pharmaceuticals (CDMO) & Myovant Sciences (MYOV)

Peregrine Pharmaceuticals (NASDAQ: CDMO) and Myovant Sciences (NYSE:MYOV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Peregrine Pharmaceuticals and Myovant Sciences, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Peregrine Pharmaceuticals 0 0 1 0 3.00
Myovant Sciences 0 0 4 0 3.00

Peregrine Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 198.51%. Myovant Sciences has a consensus price target of $22.50, indicating a potential upside of 67.16%. Given Peregrine Pharmaceuticals’ higher probable upside, research analysts clearly believe Peregrine Pharmaceuticals is more favorable than Myovant Sciences.

Valuation & Earnings

This table compares Peregrine Pharmaceuticals and Myovant Sciences’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Peregrine Pharmaceuticals $57.63 million 2.63 -$28.15 million ($0.81) -4.14
Myovant Sciences N/A N/A -$83.44 million ($1.41) -9.55

Peregrine Pharmaceuticals has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Peregrine Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Peregrine Pharmaceuticals has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500.

Insider & Institutional Ownership

18.4% of Peregrine Pharmaceuticals shares are held by institutional investors. Comparatively, 79.2% of Myovant Sciences shares are held by institutional investors. 2.5% of Peregrine Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of Myovant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


This table compares Peregrine Pharmaceuticals and Myovant Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Peregrine Pharmaceuticals -39.23% -52.55% -24.77%
Myovant Sciences N/A -53.75% -48.90%


Peregrine Pharmaceuticals beats Myovant Sciences on 8 of the 12 factors compared between the two stocks.

Peregrine Pharmaceuticals Company Profile

Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, Inc., incorporated on September 25, 1996, is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides a variety of process development activities, including cell line development and optimization.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

Receive News & Ratings for Peregrine Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply